News

PipelineReview.com10h
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
BASEL, Switzerland I August 11, 2025 I FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today ...
PipelineReview.com12h
AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus
SEOUL, South Korea I August 11, 2025 I AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead ...
PipelineReview.com12h
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
EAST HANOVER, NJ, USA I August 11, 2025 I Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults ...
PipelineReview.com12h
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, ...
PipelineReview.com12h
Target selection in drug discovery: new service offering with predefined evaluation packages
STUTTGART, Germany I August 11, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of ...
PipelineReview.com2d
RemeGen’s Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China I August 8, 2025 I On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration ...
PipelineReview.com4d
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcer ...
PipelineReview.com4d
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
Topline results from CATT1 Phase 3 trial expected in second half of 2026. HIGH POINT, NC, USA I August 07, 2025 I vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceuti ...
PipelineReview.com4d
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...
PipelineReview.com4d
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...
PipelineReview.com4d
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart ...
PipelineReview.com4d
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea I August 6, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication ...